TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents
June 2nd, 2016
Here we present a protocol for screening of a heptamer-type sgRNA library for potential therapeutic drugs against blood cancers.
The overall goal of this screening is to find potential therapeutic drugs against blood cancers.Begin this procedure by selecting a subset of Heptamer sequences.The sequences can be random, or designed to target specific cellular RNAs.To target specific cellular RNAs, use an appropriate computer program to find hairpin structures resembling the T-arm in a target RNA.Select complementary seven-nucleotide sequences immediately downstream of the hairpin.Using the phosphoramidite method on the controlled pore glass, or CPG support, synthesize each of the selected Heptamers as a fully 2-prime O-methylated, 5-prime and 3-prime phosphorylated RNA with the DNA-RNA synthesizer.Leave the 5-prime terminal DMT protecting group on in the last cycle of the synthesis.After completion of the last cycle, transfer the CPG with the synthesized oligonucleotide from the column to a glass vial with a teflon-lined screw cap.Add 1mL of 29%ammonium hydroxide and incubate the tube at 55
View the full transcript and gain access to thousands of scientific videos
Overview
This article presents a protocol for screening a heptamer-type sgRNA library aimed at identifying potential therapeutic drugs for blood cancers.
Key Study Components
Area of Science
- Neuroscience
- Oncology
- Genetic Engineering
Background
- Blood cancers pose significant treatment challenges.
- Novel therapeutic approaches are needed to improve patient outcomes.
- sgRNA libraries can facilitate targeted gene editing.
- This study focuses on a specific type of sgRNA for therapeutic screening.
Purpose of Study
- To develop a protocol for screening sgRNA libraries.
- To identify potential drug candidates for blood cancers.
- To enhance the understanding of gene editing in therapeutic contexts.
Methods Used
- Design and synthesis of heptamer-type sgRNA libraries.
- Screening protocols for evaluating therapeutic efficacy.
- Analysis of gene editing outcomes.
- Validation of potential drug candidates through experimental assays.
Main Results
- Identification of promising sgRNAs with therapeutic potential.
- Demonstration of effective screening methodology.
- Insights into the role of sgRNA in blood cancer treatment.
- Recommendations for further research and development.
Conclusions
- The protocol provides a valuable tool for drug discovery.
- Heptamer-type sgRNAs show promise in targeting blood cancers.
- Future studies should focus on clinical applications and efficacy.
